Our Journey
June 2003 - MicroOncology is founded
MicroOncology is founded by Professor Chris Hancock with a vision of improving patient outcomes across indications by bringing advanced energy to therapeutic endoscopy.
MicroOncology rebrands as Creo Medical Group and the company’s focus shifts to bringing advanced energy medical devices to market.
Craig Gulliford is appointed CEO of Creo Medical Group.
Creo Medical is listed on the London Stock Exchange.
Creo Medical Moves into Chepstow HQ.
First patient treated with Speedboat Inject.
CE Mark clearance gained for Speedboat Inject and the CROMA Advanced Energy Platform.
£48.5M raised through share placings to accelerate commercialisation.
First use of Speedboat Inject in mainland Europe and South Africa.
£51.9m raised through share placings to accelerate US programme and progress research and development.
First use of Speedboat Inject in the US and India, with first commercial orders received.
MicroBlate Fine’s first in-human use.
Acquisition of Albyn Medical S.L, Boucart Medical and Endotechnik, providing Creo with established European distribution network and wider portfolio of products.
CE Mark clearance achieved for five new devices, with FDA clearance also gained for SlypSeal Flex and Microblate Fine.
US FDA clearance for MicroBlate Flex.
Opening of US HQ in Danbury.
Creo aquires Aber Electronics Limited – enhancing additional expertise to Creo and a key element of supply chain.
Launch international Pioneer Clinical Education Programme.
Long term collaboration announced with Intuitive, with heads of terms announced to grant further third-party access to Creo’s advanced energy technology.
Creo Medical opens APAC regional hub in Singapore.
First European Speedboat® UltraSlim procedure marks early commercial launch.
